Last post Fri, May 09 2008 1:21 AM by terrylynn. 1 replies.
Results were released from a one-year prospective, observational study conducted to determine the impact of beginning treatment with AVONEX on MS patients' overall quality of life (QoL). The data showed that patients receiving treatment with AVONEX experienced statistically significant improvements in QoL, as measured by the EuroQol questionnaire (EQ-5D), compared to baseline. In addition, the study demonstrated the negative impact of disability progression (as measured by the expanded disability status scale (EDSS)) on employment status and QoL. These data were presented as a poster presentation at the 60th American Academy of Neurology annual meeting in Chicago, Illinois................ For the full report please go to MSRC: MS Research News : Drugs : Disease Modifying Drugs : Disease Modifying Drugs Ongoing Research : AVONEX® and REBIF®